股票代码：002391 股票简称：长青股份 公告编号：2024-018 江苏长青农化股份有限公司 一、募集资金有关情况 1、募集资金基本情况 经中国证券监督管理委员会《关于核准江苏长青农化股份有限公司公开发行 可转换公司债券的批复》（证监许可[2018]2097 号）核准，公司于 2019 年 2 月 27 日向社会公开发行 913.8 万张可转换公司债券，每张面值 100 元，公开发行可 转债募集资金总额为 913,800,000.00 元，扣除承销费、保荐费等发行费用 21,047,380.00 元后，本次募集资金净额为 892,752,620.00 元。募集资金到位情况 业经立信会计师事务所（特殊普通合伙）验证，并 2019 年 3 月 5 日出具了信会 师报字[2019]第 ZH10011 号《验资报告》。 公司已对募集资金采取专户存储管理，并与募投项目实施主体、保荐机构民 生证券股份有限公司、开户银行签订了《募集资金四方监管协议》。 2、募投项目情况 根据公司《公开发行可转换公司债券募集说明书》，本次公开发行可转换公 司债券总额为人民币 91,380.00 万元，由全资子公司江苏长青农化南通有限公司 ...

三、关于续聘会计师事务所的独立意见 根据中国证监会《上市公司监管指引第 8 号—上市公司资金往来、对外担保 的监管要求》及《上市公司章程指引（2022 年修订）》第 42 条和第 78 条等的规 定和要求，作为公司的独立董事，我们对公司报告期内（2023 年 1 月 1 日至 2023 年 12 月 31 日）控股股东及关联方占用资金和对外担保情况进行了认真的了解和 核查，现发表如下独立意见： （一）公司严格执行《上市公司监管指引第 8 号—上市公司资金往来、对外 担保的监管要求》，报告期内不存在控股股东及其它关联方占用公司资金的情况。 （二）公司严格执行《上市公司监管指引第 8 号—上市公司资金往来、对外 担保的监管要求》，报告期内公司不存在为控股股东及其他关联方、任何非法人 单位或个人提供担保的情况。报告期末，公司为全资子公司长青（湖北）生物科 技有限公司向中国建设银行股份有限公司贷款人民币 2 亿元，向中国农业银行股 份有限公司贷款人民币 4 亿元提供全额连带责任保证担保，全资子公司江苏长青 农化南通有限公司为公司向中国进出口银行江苏省分行贷款人民币 3 亿元提供 全额连带责任保证担保，有利于公司业务的 ...

一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是长青股份董事会的责任。 内部控制审计报告 信会师报字[2024]第 ZH10081 号 江苏长青农化股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了江苏长青农化股份有限公司（以下简称"长青股 份"）2023 年 12 月 31 日的财务报告内部控制的有效性。 我们认为，长青股份于 2023 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 内控审计报告 第 1 页 （特殊普通合伙） 立信会计师事务所 中国注册会计师：张爱国 中国注册会计师：李凌 中国•上海 二〇二四年四月十六日 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可 ...

江苏长青农化股份有限公司 独立董事 2023 年度述职报告 （李钟华） 尊敬的各位股东： 作为江苏长青农化股份有限公司（以下简称"公司"）独立董事，2023年度， 根据《公司法》、《上市公司独立董事管理办法》、《关于加强社会公众股股东 权益保护的若干规定》、《上市公司自律监管指引第1号——主板上市公司规范 运作》等法律和其他规范性文件，以及《公司章程》、《独立董事工作制度》的 规定和要求，恪尽职守、勤勉尽责，积极出席相关会议，认真审议董事会各项议 案，对公司相关事项发表独立意见，充分发挥独立董事的独立作用，切实维护公 司和股东，尤其是中小股东的利益。现将2023年度本人履职情况汇报如下： 一、出席会议情况 本人本着勤勉尽责的态度积极参加公司2023年度召开的董事会和股东大会， 在会议召开之前均主动了解并获取作出决策所需要的情况和资料，了解公司生产 运作和经营情况，会议上认真审阅每项议案，积极参与各项议题的讨论并提出合 理化建议，为董事会作出正确、科学的决策发挥积极作用。 | 姓名 | 应出席董事会 | 现场出席 | 以通讯方式参加 | 委托出席 | 缺席次数 | | --- | --- | --- | --- ...

Financial Performance - The company's revenue for Q1 2024 was ¥859,885,614.78, a decrease of 15.84% compared to ¥1,021,723,217.16 in the same period last year[18] - Net profit attributable to shareholders was ¥7,903,609.81, down 91.26% from ¥90,412,091.70 year-on-year[18] - Basic earnings per share decreased by 91.20% to ¥0.0122 from ¥0.1387 in the same period last year[18] - Total operating revenue for the first quarter was ¥859,885,614.78, a decrease of 15.8% compared to ¥1,021,723,217.16 in the previous period[41] - The company's net profit for the current period is 7,902,233.59, a significant decrease from 90,806,000.14 in the previous period[43] - Total profit for the current period is 7,497,716.12, compared to 11,404,219.09 in the previous period, reflecting a decline[43] Cash Flow - The net cash flow from operating activities was -¥135,368,776.32, representing a decline of 404.58% compared to -¥26,827,951.45 in the previous year[18] - The net cash flow from operating activities decreased by 404.58% to -135,368,776.32 RMB, primarily due to a reduction in cash received from sales of goods and services[22] - Cash inflow from investment activities totaled ¥387,707,436.70, a decrease of 53.8% from ¥839,285,363.82 in the prior year[31] - Cash outflow from investment activities was ¥636,239,541.01, down 41.0% from ¥1,079,413,672.29 in the previous period[31] - The company reported a net cash flow from investment activities of -¥248,532,104.31, slightly worse than -¥240,128,308.47 in the prior year[31] - The net cash flow from financing activities is 384,620,801.97, an increase from 149,676,724.00 in the previous period[45] - The company reported a net cash outflow of -2,287,519.12, compared to -118,104,172.68 in the previous period[45] Assets and Liabilities - Total assets increased by 6.87% to ¥8,603,884,459.82 from ¥8,050,482,608.58 at the end of the previous year[18] - The total liabilities increased to 2,727,079,753.88 RMB, compared to 1,647,924.48 RMB, indicating a significant rise in financial obligations[25] - Long-term borrowings increased by 63.12% to ¥1,106,869,434.61, attributed to loans for fixed asset projects and long-term working capital[21] - Long-term borrowings increased to ¥1,106,869,434.61 from ¥678,559,932.82, reflecting a significant rise in debt[41] - Total liabilities rose to ¥4,059,141,283.93, compared to ¥3,469,554,960.86 in the previous period, indicating increased financial leverage[41] Investments and Fair Value - The company reported a significant increase of 3679.32% in fair value gains to ¥5,313,779.56, mainly due to the settlement of forward foreign exchange contracts[21] - The company reported a fair value change gain of 5,313,779.56, contrasting with a loss of 148,457.76 in the previous period[43] - The company’s investment income showed a loss of -1,679,239.17, a decline from a gain of 5,098,629.92 in the previous period[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,532, with the largest shareholder holding 25.40% of the shares[22] - The company’s total equity decreased to ¥4,544,743,175.89 from ¥4,580,927,647.72, showing a slight decline in shareholder value[41] Other Financial Metrics - The company recorded a net loss of ¥2,344,240.60 from non-recurring gains and losses, primarily due to charitable donations[18] - The company incurred interest expenses of 20,569,574.65, up from 18,707,765.75 in the previous period[43] - The company experienced a credit impairment loss of -5,451,947.26, worsening from -1,530,930.35 in the previous period[43] - The company’s cash and cash equivalents decreased to 387,936,348.37 RMB from 401,678,123.47 RMB, a decline of approximately 3.67%[24] - The inventory balance increased to 1,753,600,956.26 RMB, up from 1,629,224,554.92 RMB, reflecting a growth of about 7.63%[24] - The company’s long-term equity investments decreased slightly to 22,696,100.00 RMB from 24,694,100.00 RMB, a decline of about 8.09%[25] - The company’s income tax expense decreased by 142.27% to -3,919,970.93 RMB, primarily due to a decline in profits[22]

Financial Performance - The company's operating revenue for 2023 was approximately ¥3.61 billion, a decrease of 14.83% compared to ¥4.24 billion in 2022[13]. - Net profit attributable to shareholders was approximately ¥73.11 million, down 72.13% from ¥262.35 million in the previous year[13]. - The basic earnings per share decreased to ¥0.1126, a decline of 72.02% from ¥0.4024 in 2022[13]. - Total revenue for Q1 2023 was approximately CNY 1.02 billion, while Q4 2023 revenue decreased to about CNY 824.85 million, reflecting a decline of 19.3% from Q1[29]. - The net profit attributable to shareholders for Q4 2023 was a loss of approximately CNY 142 million, compared to a profit of CNY 90.41 million in Q1 2023, indicating a significant downturn[29]. - Non-recurring gains and losses totaled approximately CNY -12.68 million for 2023, compared to a gain of CNY 8.41 million in 2022, highlighting a deterioration in financial performance[31]. - The company's total operating cost for 2023 was approximately ¥2.7 billion, with the agricultural chemicals segment accounting for 87.85% of this cost, a 9.02% increase from the previous year[106]. - Financial expenses surged by 133.62% to ¥62,319,820.42, primarily due to increased bank loan interest and reduced foreign exchange gains[115]. - R&D expenses decreased by 13.91% to ¥174,402,822.21, representing 4.83% of total revenue[126]. Assets and Liabilities - The total assets at the end of 2023 were approximately ¥8.05 billion, an increase of 7.71% from ¥7.47 billion at the end of 2022[13]. - The net assets attributable to shareholders decreased slightly by 1.26% to approximately ¥4.58 billion from ¥4.64 billion in 2022[13]. - The total liabilities increased by 22.85% to CNY 346,955.50 million compared to the beginning of the year[71]. - The company's inventory accounted for 20.24% of total assets at the end of 2023, up from 19.07% at the beginning of the year[139]. - Short-term borrowings increased to 1,337,750,693.07 yuan, representing 16.62% of total assets, up from 11.09% at the beginning of the year[139]. Market and Industry Trends - The global pesticide market size grew from $35.575 billion in 2006 to $87.7 billion in 2022, with a compound annual growth rate of approximately 5.80%[26]. - The global agricultural chemical industry is experiencing consolidation, with major players like Syngenta and Bayer controlling over 60% of the market, which may impact competitive dynamics[33]. - The focus of the pesticide industry is shifting towards high-efficiency, low-toxicity, and low-residue new environmentally friendly pesticides, with new formulations like water-dispersible granules and controlled-release agents being rapidly developed and promoted[194]. - China is the world's largest pesticide exporter with 1,775 existing pesticide production enterprises, entering a new round of industry consolidation due to intensified competition and environmental pressures[191]. Production and Innovation - The company produced 30,390 tons of active ingredients in 2023, an increase of 46.51% year-on-year[71]. - The company has successfully introduced 30 new pesticide varieties with independent intellectual property rights, covering over 300 million mu of land, demonstrating its innovation capabilities[60]. - The company is focusing on the development of high-efficiency, low-toxicity, and low-residue new environmental-friendly pesticides as a key trend in the industry[169]. - The company has established multiple standardized production workshops to enhance production capacity and efficiency, ensuring high-quality products at competitive prices[95]. - The company has achieved production yield levels comparable to leading international pesticide companies, maintaining a high gross margin in its main business[97]. Sales and Marketing - Revenue from the pesticide segment was approximately ¥3.52 billion, accounting for 97.39% of total revenue, down 15.57% from ¥4.17 billion in 2022[81]. - Domestic sales reached CNY 170,491.06 million, reflecting a growth of 16.76% year-on-year[71]. - The company is focusing on enhancing its marketing strategies and expanding its international market presence[65]. - The company has a comprehensive marketing network covering all 30 provinces in China, enhancing its sales capabilities[108]. - The top five customers accounted for 44.46% of the total annual sales, indicating a significant reliance on a limited customer base[111]. Research and Development - The company plans to continue investing in R&D to enhance product offerings and maintain competitiveness in the market[84]. - The company’s R&D personnel increased by 6.40% to 366, with a notable rise in master's degree holders by 50.00%[126]. - The company is developing new products such as the "Fluazinam" and "Butyl Potassium," aiming for new profit growth points[123]. - The company is committed to increasing R&D investment to enhance the technological content and added value of pesticide products, aiming for a shift towards high-end product manufacturing[169]. Risks and Challenges - The company is facing risks related to industry competition, capacity expansion, and raw material price fluctuations, which could affect future performance[43]. - The company anticipates capacity expansion risks as new projects come online, which may not align with market demand, potentially affecting sales and profitability[179]. - Raw material price fluctuations pose a risk, as they account for approximately 70% of production costs, impacting the company's profitability despite its strong cost transfer capabilities[179]. - The company faces price competition risks due to the low market concentration in the pesticide industry, which may lead to declining product prices and profit margins[179]. - The company is subject to increasing regulatory pressures regarding environmental protection, which may raise operational costs and affect profitability[182]. Future Plans - The company aims for a revenue target of 4 billion yuan for 2024, representing a 10.67% increase compared to 2023[177]. - The company plans to expand its marketing team and enhance product structure to capture a larger share of the domestic formulation market[177]. - The company will focus on high-efficiency, low-toxicity, and low-residue pesticide research, production, and sales[177]. - The company intends to increase overseas registration of raw materials and formulations to build a global sales network[177]. - The company will prioritize safety management to ensure stable production operations across its facilities[177].

江苏长青农化股份有限公司董事会 关于 2023 年度内部控制自我评价报告 江苏长青农化股份有限公司董事会 关于 2023 年度内部控制自我评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称 "企业内部控制规范体系"），结合江苏长青农化股份有限公司（以下简称"公司"）内部 控制制度和评价方法，在内部控制日常监督和专项监督的基础上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 公司内部控制的目标：建立和完善符合现代企业管理要求的内部组织架构，形成科学的决 策机制、执行机制和监督机制；建立行之有效的内部控制系统，强化风险管理，保证公司 各项业务活动的正常有序运行；严格遵守国家有关法律法规和行业规章，自觉形成守法经 营、规范运作的经营思想；预防和控制各种错误和弊端的发生，消除隐患，合理保证经营 管理合法合规、资产安全、财务报告及相关信息真实完整，提高经营效率和效果，促进公 司经营目标和发展战略的实现。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可能导致内部控制变得不恰 ...

江苏长青农化股份有限公司 独立董事 2023 年度述职报告 （骆广生） 尊敬的各位股东： 作为江苏长青农化股份有限公司（以下简称"公司"）独立董事，2023年度， 根据《公司法》、《上市公司独立董事管理办法》、《关于加强社会公众股股东 权益保护的若干规定》、《上市公司自律监管指引第1号——主板上市公司规范 运作》等法律和其他规范性文件，以及《公司章程》、《独立董事工作制度》的 规定和要求，恪尽职守、勤勉尽责，积极出席相关会议，认真审议董事会各项议 案，对公司相关事项发表独立意见，充分发挥独立董事的独立作用，切实维护公 司和股东，尤其是中小股东的利益。现将2023年度本人履职情况汇报如下： 一、出席会议情况 本人本着勤勉尽责的态度积极参加公司2023年度召开的董事会和股东大会， 在会议召开之前均主动了解并获取作出决策所需要的情况和资料，了解公司生产 运作和经营情况，会议上认真审阅每项议案，积极参与各项议题的讨论并提出合 理化建议，为董事会作出正确、科学的决策发挥积极作用。 | 姓名 | 应出席董事会 | | 现场出席 | 以通讯方式参加 | 委托出席 | 缺席次数 | | --- | --- | --- | - ...

民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为江苏 长青农化股份有限公司（以下简称"长青股份"或"公司"）公开发行可转换公 司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等相关法律法规及规范性文件的规定，对本次公司公开发行可转换公司 债券部分暂时闲置募集资金进行现金管理事项进行了核查，具体情况如下： 一、本次募集资金有关情况 （一）本次募集资金基本情况 民生证券股份有限公司 关于江苏长青农化股份有限公司 继续使用暂时闲置募集资金进行现金管理的专项核查意见 经中国证券监督管理委员会《关于核准江苏长青农化股份有限公司公开发行 可转换公司债券的批复》（证监许可[2018]2097 号）核准，公司于 2019 年 2 月 27 日向社会公开发行 913.8 万张可转换公司债券，每张面值 100 元，公开发行可转 债募集资金总额为 913,800,000.00 元，扣除承销费、保荐费等发行费用 21,047,380.00 ...

江苏长青农化股份有限公司 独立董事 2023 年度述职报告 （龚新海） 尊敬的各位股东： 作为江苏长青农化股份有限公司（以下简称"公司"）独立董事，2023年度， 根据《公司法》、《上市公司独立董事管理办法》、《关于加强社会公众股股东 权益保护的若干规定》、《上市公司自律监管指引第1号——主板上市公司规范 运作》等法律和其他规范性文件，以及《公司章程》、《独立董事工作制度》的 规定和要求，恪尽职守、勤勉尽责，积极出席相关会议，认真审议董事会各项议 案，对公司相关事项发表独立意见，充分发挥独立董事的独立作用，切实维护公 司和股东，尤其是中小股东的利益。现将2023年度本人履职情况汇报如下： 一、出席会议情况 本人本着勤勉尽责的态度积极参加公司2023年度召开的董事会和股东大会， 在会议召开之前均主动了解并获取作出决策所需要的情况和资料，了解公司生产 运作和经营情况，会议上认真审阅每项议案，积极参与各项议题的讨论并提出合 理化建议，为董事会作出正确、科学的决策发挥积极作用。 2023年，公司董事会、股东大会的召集召开符合法定程序，重大经营决策事 1 项均履行了相关程序，合法有效。本人对各次董事会会议审议的相关议案 ...